Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-118 in pancreatobiliary cancers
jRCT2031260448Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of telisotuzumab adizutecan, gemcitabine and paclitaxel in pancreaticobiliary cancer, sponsored by AbbVie Inc. Primary endpoints: Overall response and Adverse events. Started Aug 2026; status: recruiting.
02
Drugs
telisotuzumab adizutecangemcitabinepaclitaxel
03
Conditions
pancreaticobiliary cancer
Beyond the preview
Go deeper on jRCT2031260448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260448.